Evidence map›Paper›PMID 40265022›Full record

ArticleFrontiers in oncology2025

The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC.

Yuling Su, Siwen Qiu, Jinyu Wang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuling SuDepartment of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
Siwen QiuDepartment of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
Jinyu WangDepartment of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the value of Fluorine-18 Fluorodeoxyglucose ( Methods: A retrospective review was performed for patients who underwent PET/CT and curative resection of NSCLC between January 2016 and June 2019 in our hospital. PET/CT data, clinical features, and pathology results were collected. Gross tumor volume (GTV) was delineated on CT images by ITK-SNAP software. The prognosis was followed up, and the study endpoint was progression-free survival (PFS). Receiver operating characteristic curve (ROC) was used to initially assess the relationship between each parameter and PFS, and parameters were grouped accordingly. Cox proportional hazards regression was used to develop models based on clinicopathological features to predict prognosis of NSCLC patients. Kaplan-Meier method was used to draw the survival curves. Results: A total of 128 patients were enrolled in the study with PFS of 8-96 months. Univariate analysis demonstrated that age, SUVindex (the ratio of SUVmax of lesion to SUVmax of liver), metabolic tumor volume (MTV), Dmax (the largest diameter), GTV, lymph node metastasis (LNM), and TNM staging are significantly related to recurrence (all p<0.05). The multivariate analysis showed that only age, SUVindex, and LNM were independent prognostic factor for PFS (all p < 0.05). Conclusions: Although 18F-FDG PET/CT combined with 3D quantitative technique were helpful in predicting PFS in NSCLC, only age, SUVindex, and LNM were independent predictors for PFS.

Indexed as

3D quantitative technologylung cancerNSCLCPET/CTprognosis

Identifiers

PMID40265022
PMCPMC12011598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.